Literature DB >> 28791833

History of discovery of polycystic ovary syndrome.

.   

Abstract

Stein and Leventhal are regarded to have been the first investigators of polycystic ovary syndrome (PCOS); however, in 1721 Vallisneri, an Italian scientist, described a married, infertile woman with shiny ovaries with a white surface, and the size of pigeon eggs. It was not until the early 1990s at a National Institute of Health (NIH) sponsored conference on PCOS that formal diagnostic criteria were proposed and afterwards largely utilized. Many scientists tried to explain the pathophysiology of PCOS and many studies were made. It is now accepted that it is multifactorial, partly genetic; however, a number of candidate genes have been postulated. Insulin resistance has been noted consistently among many women with PCOS, especially in those with hyperandrogenism, but it is not included in any of the diagnostic criteria. Now there is strong evidence that cardiovascular disease risk factors and disturbances in carbohydrate metabolism are all increased in patients with PCOS compared to the healthy population. The criteria established by a group of experts during a conference in Rotterdam held in 2003 are obligatory (The Rotterdam ESHRE/ASRM - Sponsored PCOS Consensus Workshop Group). The subsequent "Rotterdam criteria" incorporated the size and morphology, as determined by an ultrasound, of the ovary into the diagnostic criteria.

Entities:  

Keywords:  hyperandrogenism; infertile; polycystic ovary syndrome

Mesh:

Year:  2017        PMID: 28791833     DOI: 10.17219/acem/61987

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  6 in total

1.  Association of SNPs in the FK-506 binding protein (FKBP5) gene among Han Chinese women with polycystic ovary syndrome.

Authors:  Xinyue Ma; Zhao Wang; Changming Zhang; Yuehong Bian; Xin Zhang; Xin Liu; Yongzhi Cao; Yueran Zhao
Journal:  BMC Med Genomics       Date:  2022-07-04       Impact factor: 3.622

2.  Integrated Network Pharmacology and Clinical Study to Reveal the Effects and Mechanisms of Bushen Huoxue Huatan Decoction on Polycystic Ovary Syndrome.

Authors:  Jie Ding; Mei Shanshan; Cai Mengcheng; Zhang Danying; Yu Jin
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-13       Impact factor: 2.650

3.  CTBP1‑AS upregulation is associated with polycystic ovary syndrome and can be effectively downregulated by cryptotanshinone.

Authors:  Mingxiao Wen; Xiaoqing Dou; Shuzhen Zhang; Bin Wang; Jiangyan Xu; Wenchao Zhang; Feifei Wang
Journal:  Mol Med Rep       Date:  2022-06-03       Impact factor: 3.423

4.  Cangfu daotan decoction for polycystic ovary syndrome: A protocol of systematic review and meta-analysis.

Authors:  Hye-Rin Park; Jong-Hwan Kim; Donghun Lee; Hee-Geun Jo
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

Review 5.  Effects of Vitamin D on Fertility, Pregnancy and Polycystic Ovary Syndrome-A Review.

Authors:  Szabolcs Várbíró; István Takács; László Tűű; Katalin Nas; Réka Eszter Sziva; Judit Réka Hetthéssy; Marianna Török
Journal:  Nutrients       Date:  2022-04-15       Impact factor: 6.706

6.  Evaluation of Endocrine and Metabolic Changes in Polycystic Ovary Syndrome by Ultrasonic Imaging Features under an Intelligent Algorithm.

Authors:  Li Wei; Feng Wu; Jianjun Zhang; Jing Li; Di Yang; Guoying Wen
Journal:  Comput Math Methods Med       Date:  2022-04-26       Impact factor: 2.809

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.